A
12.17
0.37 (3.14%)
| Previous Close | 11.80 |
| Open | 12.20 |
| Volume | 694,113 |
| Avg. Volume (3M) | 632,839 |
| Market Cap | 492,467,584 |
| Price / Earnings (Forward) | 96.15 |
| Price / Sales | 1.76 |
| Price / Book | 2.72 |
| 52 Weeks Range | |
| Earnings Date | 2 Apr 2025 - 7 Apr 2025 |
| Profit Margin | -83.02% |
| Operating Margin (TTM) | -12.91% |
| Diluted EPS (TTM) | -5.59 |
| Quarterly Revenue Growth (YOY) | -14.20% |
| Total Debt/Equity (MRQ) | 2.76% |
| Current Ratio (MRQ) | 2.25 |
| Operating Cash Flow (TTM) | -20.51 M |
| Levered Free Cash Flow (TTM) | 24.19 M |
| Return on Assets (TTM) | -6.12% |
| Return on Equity (TTM) | -77.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | AngioDynamics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 5.60% |
| % Held by Institutions | 81.30% |
| 52 Weeks Range | ||
| Median | 15.00 (23.25%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Jan 2025 | 15.00 (23.25%) | Buy | 12.30 |
| 10 Dec 2024 | 14.00 (15.04%) | Buy | 8.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI |
| 08 Jan 2025 | Announcement | AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results |
| 06 Jan 2025 | Announcement | AngioDynamics to Present at the J.P. Morgan Healthcare Conference |
| 06 Jan 2025 | Announcement | AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System |
| 19 Dec 2024 | Announcement | AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event |
| 09 Dec 2024 | Announcement | AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |